Chimeric Peptide Composition for Tumor Cell Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer therapies face challenges in effectively penetrating target cells and achieving synergistic cytotoxic and cytostatic effects due to issues with bioavailability and stability of cyclin kinase inhibitors, particularly with the need for complex multi-step synthesis of chimeric peptides.
Innovation Solution
A pharmaceutical composition comprising a chimeric peptide with a functional sequence of cyclin kinase inhibitor p16INK4a or p21/CIP/KIP linked to a transport sequence, combined with therapeutically active agents like 5-fluorouracil or etoposide, and a pharmaceutically acceptable carrier, designed to enhance antiproliferative and cytotoxic activity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chimeric peptides are used to improve cell penetration and antiproliferative activity, then cytotoxic and cytostatic effects are enhanced, but the synthesis becomes complex and multi-step
Solution Approach 1:
The patent combines a cyclin kinase inhibitor sequence (p16INK4a or p21) with a cell-penetrating transport sequence (Tat or pAntp) to create chimeric peptides. This merging allows the single molecule to simultaneously achieve cell penetration and antiproliferative effects, resolving the contradiction between enhanced activity and synthesis complexity by creating a unified structure rather than requiring separate steps
Solution Approach 2:
The chimeric peptides represent composite molecular structures combining two functional sequences with distinct properties. The cyclin kinase inhibitor domain provides antiproliferative activity while the transport domain provides cell penetration capability, creating a composite molecule that achieves multiple functions in one synthesized entity
2Reliability
If cyclin kinase inhibitors are used to treat cancer, then cell cycle regulation is restored, but bioavailability and stability are insufficient
Solution Approach 1:
The transport sequence (Tat or pAntp) acts as an intermediary that facilitates the delivery of the cyclin kinase inhibitor into the cell. This intermediary component enables the inhibitor to overcome bioavailability barriers and reach its intracellular target, resolving the contradiction between therapeutic effect and bioavailability
Solution Approach 2:
By changing the molecular parameters of the cyclin kinase inhibitor through conjugation with transport sequences, the patent modifies key properties including cellular uptake efficiency, intracellular stability, and bioavailability. This parameter change allows the same functional domain to achieve improved stability and delivery without altering its core inhibitory mechanism
3Ease of manufacture
If traditional chemotherapeutic agents are used, then treatment is simpler, but penetration into target cells and synergistic effects are limited
Solution Approach 1:
The patent merges the simplicity of using established chemotherapeutic agents with the enhanced penetration capability of cell-penetrating sequences. The chimeric peptide structure combines the therapeutic payload (cyclin kinase inhibitor) with a delivery system (transport sequence), achieving both ease of administration and improved cellular uptake and synergistic cytotoxic effects
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the field of biotechnology and medicine, in particular to a pharmaceutical composition having an antiproliferative activity, and to a method of treating oncological diseases, comprising introducing the aforementioned chimeric peptide to a mammal requiring such treatment. The object of the invention is the development of a preparation that effectively penetrates the target cells and has a high cytostatic and cytotoxic action.